Investigational drug · Phase 3
include docetaxel
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Oesophageal Squamous Cell Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 24, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
166
Any phase or sponsor naming "include docetaxel"
First trial start
2024
Oct 31, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "include docetaxel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Oesophageal Squamous Cell Carcinoma
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "include docetaxel" as an intervention, largest first.
Sungkyunkwan UniversityAcademic, hospital or other
NCT04115410 · 4,724 participants (planned) · Start Jul 1, 2020 · Primary completion Sep 23, 2021
Drug: PD-1 inhibitor; Chemotherapy Drugs, Cancer · For: Carcinoma, Non-Small-Cell Lung; Immune-Related Adverse Events
BayerBayer (BAYRY)
NCT07344779 · 1,600 participants (planned) · Start Jan 29, 2026 · Primary completion Dec 31, 2029
Drug: Darolutamide (BAY 1841788); ADT and 1 more · For: Metastatic Hormone-Sensitive Prostate Cancer
Sites: Many Locations, Belgium; Many Locations, Finland; Many Locations, France · 16 sites in all
Rawalpindi Medical CollegeAcademic, hospital or other
NCT05931042 · 1,209 participants · Start Jun 1, 2023 · Primary completion Jun 15, 2023
Drug: Trastuzumab · For: HER2+ Breast Cancer
Sites: Rawalpindi, Pakistan
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03178552 · 1,000 participants (planned) · Start Sep 22, 2017 · Primary completion Jun 30, 2027
Drug: Alectinib; Atezolizumab and 10 more · For: Non-Small Cell Lung Cancer
Sites: Sacramento, California; Denver, Colorado; Fort Myers, Florida · 161 sites in all
- Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04634877 · 990 participants (planned) · Start Jan 10, 2021 · Primary completion Nov 20, 2026
Drug: Pembrolizumab; Carboplatin and 5 more · For: Endometrial Neoplasms
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 231 sites in all
BayerBayer (BAYRY)
NCT05149131 · 960 participants · Start Jan 17, 2022 · Primary completion Aug 16, 2022
Drug: ADT (Eligard®*) with or without treatment intensification · For: Metastatic Castration-sensitive Prostate Cancer
Sites: Multiple Locations, Canada
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06855277 · 940 participants (planned) · Start Jul 1, 2025 · Primary completion Sep 29, 2028
Drug: AAA817; ARPI and 1 more · For: Prostate Cancer
Sites: Homewood, Alabama; Tucson, Arizona; Orange, California · 106 sites in all
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05296798 · 922 participants (planned) · Start Jul 18, 2022 · Primary completion Jun 15, 2028
Drug: Phesgo; Giredestrant and 4 more · For: Locally Advanced or Metastatic Breast Cancer
Sites: Tucson, Arizona; Los Angeles, California; Jacksonville, Florida · 198 sites in all
- Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruiting
ExelixisIndustry
NCT03170960 · 914 participants · Start Sep 5, 2017 · Primary completion Feb 21, 2023
Drug: cabozantinib; atezolizumab and 2 more · For: Urothelial Carcinoma; Renal Cell Carcinoma; Non-Small Cell Lung Cancer and 11 more
Sites: Gilbert, Arizona; Phoenix, Arizona; Duarte, California · 124 sites in all
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate CancerPivotal-lookingCompleted
ECOG-ACRIN Cancer Research GroupResearch network
NCT00309985 · 790 participants · Start Sep 26, 2006 · Primary completion Dec 23, 2013
Drug: androgen-deprivation therapy; docetaxel · For: Metastatic Hormone-sensitive Prostate Cancer
Sites: Anchorage, Alaska; Fairbanks, Alaska; Phoenix, Arizona · 343 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Oesophageal Squamous Cell Carcinoma
- simmitinibPhase 33 trials
Shanghai Runshi Pharmaceutical Technology Co., Ltd · Advanced Oesophageal Squamous Cell Carcinoma, Advanced Solid Tumor, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.